Circulating tumor markers have been paid more attention in the application of the treatment for breast cancer

the level of which has extended from protein to gene

including traditional tumor markers

HER-2 extracellular domain

circulating tumor cells

circulating tumor DNA (ctDNA)

circulating RNA (ctRNA) and so on. As “liquid detection”

the detection of circulating tumor markers with real-time dynamic

easy operation

good reproducibility and other advantages are widely used in aiding early diagnosis

determining prognosis

prospectively predicting response or resistance to specific therapies

surveillance after primary surgery

and monitoring therapy in patients with advanced disease

The further study of circulating tumor markers may contribute to patient’s individual treatment.